Jacqueline Lehmann‐Che

Author

Also Known As

J Lehmann-Che, J. Lehmann-Che, JACQUELINE LEHMANN-CHE, Jacqueline Lehman-Che, Jacqueline Lehmann-Che, Jacqueline Lehmann‐Che, Jaqueline Lehmann-Che, Lehmann-Che, Jacqueline, M. Polivka

208

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

Inserm Université Paris Cité Hôpital Saint-Louis Assistance Publique – Hôpitaux de Paris Centre National de la Recherche Scientifique

About

Jacqueline Lehmann‐Che is an author at Inserm specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	18	2.3K
2	Natural Sciences	2	2	103
3	Engineering	1	1	391
4	Health Sciences	1	1	113
5	Anatomy	1	1	14

Jacqueline Lehmann‐Che

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
A Cellular MicroRNA Mediates Antiviral Defense in Human Cells Charles‐Henri Lecellier, Patrice Dunoyer, Khalil Arar, Science Cellular MicrornaHuman CellsImmunologyVirologyLong Non-coding Rna	2005	895
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer David Groheux, Sylvie Giacchetti, Jean‐Luc Moretti, European Journal of Nuclear Medicine and Molecular Imaging Breast OncologyEngineeringHigh 18F-fdg UptakeMedicineMolecular Imaging	2010	391
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) Thomas Cluzeau, Marie Sébert, Ramy Rahmé, Journal of Clinical Oncology	2021	256
Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen Philippe Bertheau, Elisabeth Turpin, David S. Rickman, PLoS Medicine	2007	173
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine Cécile Bally, Lionel Adès, Aline Renneville, Leukemia Research Hematological MalignancyMedicineAcute Myeloid LeukemiaPrognostic ValueMixed-phenotype Acute Leukemia	2014	157
High Frequency of <i>TP53</i> Mutation in <i>BRCA1</i> and Sporadic Basal-like Carcinomas but not in <i>BRCA1</i> Luminal Breast Tumors Élodie Manié, Anne Vincent‐Salomon, Jacqueline Lehmann‐Che, Cancer Research	2009	151
Synergistic effects of PRIMA-1<sup>Met</sup> (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemia Nabih Maslah, Norman Salomao, Louis Drevon, Haematologica	2019	135
Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma Hana Janoušková, Anne Maglott, David Y. Léger, Cancer Research α5 IntegrinHigh-grade GliomasCancer BiologyGliomaTumor Biology	2012	115
Distinct <i>tumor protein p53</i> mutants in breast cancer subgroups Anne Dumay, Jean‐Paul Feugeas, Evelyne Wittmer, International Journal of Cancer Breast OncologyEndocrine-related CancerTumor HeterogeneityMedicineCancer Cell Biology	2012	113
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 Jacqueline Lehmann‐Che, Anne‐Sophie Hamy, Raphaël Porcher, Breast Cancer Research	2013	98

Page 1